Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078662 · ClinicalTrials.gov registry record · Phase 2
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
NCT01078662 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 298 participants.
The verdict
NCT01078662, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
Study Summary
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
Interventions
- DRUG olaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2010-02-21 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078662
The ClinicalTrials.gov registry entry for NCT01078662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which olaparib is the first listed.
NCT01078662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01078662 about?
NCT01078662 is a clinical study titled "Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats". To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
What is the current status of trial NCT01078662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2010-02-21. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT01078662?
The interventions under investigation include: olaparib (DRUG).
Who is sponsoring clinical trial NCT01078662?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.